Clinical data | |
---|---|
Other names | 5-OCF3-DMT |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
Chemical and physical data | |
Formula | C13H15F3N2O |
Molar mass | 272.271 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
5-TFMO-DMT (5-(trifluoromethoxy)-DMT, 5-OCF3-DMT, 5-(trifluoromethoxy)-N,N-dimethyltryptamine) is a psychedelic tryptamine derivative related to drugs such as 5-MeO-DMT and DMT (DMT). It acts as an agonist at the 5-HT2A receptor with an EC50 of 127.2 nM. It was shown to release serotonin (5-HT) from synaptosomal preparations, and to reduce immobility time in the forced-swim test in animal studies, suggesting that it might have antidepressant activity.
See also
References
- ^ WO 2022/235927, Kruegel AC, "NOVEL TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS.", published 10 November 2022, assigned to Gilgamesh Pharmaceuticals, Inc..
Tryptamines | |
---|---|
Tryptamines |
|
N-Acetyltryptamines |
|
α-Alkyltryptamines |
|
Triptans | |
Cyclized tryptamines |
|
Isotryptamines | |
Related compounds |
|
This hallucinogen-related article is a stub. You can help Misplaced Pages by expanding it. |